Open-label Study of TAK-875.

Trial Profile

Open-label Study of TAK-875.

Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Fasiglifam (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 01 Nov 2011 Status changed from not yet recruiting to recruiting as reported by
    • 16 Sep 2011 New source identified and integrated ( record NCT01433419)
    • 14 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top